India, July 17 -- Corona Remedies has announced the acquisition of seven brands from the pharmaceutical division of Bayer in India.

EffectiveJuly 16, 2025, the acquisition encompasses several brands within thecardiology segment (NOKLOT)and thewomen's healthcare portfolio (FOSTINE, LUPROFACT, MENODAC, OVIDAC, SPYE, and VAGESTON)for the Indian market.

This strategic move strengthens Corona Remedies position in both thecardiology and women's healthcare segments. These products propose to offer growth under CORONA Remedies stewardship going forward.

Integrating these acquired brands into its portfolio marks Corona Remedies entry into the anti-platelet market, which is valued atRs 1507 crorewith an8%growth rate. Furthermore, it aims to stre...